Best Hospitals for Head and Neck Cancer Treatment in Mumbai, India

Head and neck cancers are a heterogeneous group of malignancies, the vast majority (>90%) being squamous cell carcinomas (HNSCC), arising from the mucosal epithelium lining the upper aerodigestive tract. Primary subsites include the oral cavity (lips, tongue, floor of mouth, buccal mucosa), oropharynx (base of tongue, tonsils, soft palate — increasingly driven by high-risk HPV-16 infection), larynx (supraglottic, glottic, subglottic), hypopharynx, nasopharynx, and major and minor salivary glands. Thyroid malignancies — papillary, follicular, medullary, and anaplastic — are categorized separately but managed within head and neck oncology programs. Risk factors include tobacco and alcohol synergy, betel nut chewing (prevalent across South and Southeast Asia), HPV infection (particularly oropharyngeal), Epstein-Barr virus (nasopharyngeal), and prior radiation exposure.

• ELIGIBLE CANDIDATES:
• Newly diagnosed head and neck squamous cell carcinoma (HNSCC) of any subsite, confirmed by endoscopic biopsy with histopathological analysis including HPV/p16 status (via IHC and/or PCR), EBV serology (nasopharyngeal), and PD-L1 Combined Positive Score (CPS)
• Patients with differentiated thyroid cancer (papillary or follicular) of any risk category, or medullary thyroid cancer with germline RET mutation analysis
• Locally advanced disease (Stage III–IVB) being evaluated for organ-preservation concurrent chemoradiation vs. primary surgical resection with reconstruction
• Recurrent or metastatic HNSCC previously treated with platinum-based therapy, now eligible for immunotherapy (pembrolizumab, nivolumab) or targeted therapy (cetuximab — anti-EGFR)
• +22 more

Surgical APPROACHES:

• Transoral Robotic Surgery (TORS): Using the da Vinci Xi or SP (single-port) robotic system, TORS enables resection of oropharyngeal (tonsil, base of tongue), supraglottic, and selected hypopharyngeal lesions through the mouth without external incisions. Advantages include three-dimensional magnified visualization, tremor-filtered wristed instrumentation, negative margin rates comparable to open surgery, dramatically reduced hospital stay (3–5 days), faster swallowing recovery, and avoidance of mandibulotomy. Indicated for T1–T2 tumors with adequate transoral access. Simultaneous ipsilateral or bilateral selective neck dissection (Levels I–IV or II–IV) is performed transcervically.
• Transoral Laser Microsurgery (TLM): CO₂ laser-based endoscopic resection via direct laryngoscopy under general anesthesia. Highly effective for early glottic (T1a, T1b, T2) and supraglottic lesions, offering laryngeal preservation with excellent voice outcomes. Tumor is resected in multiple passes with histopathologic margin assessment guiding extent.
• Open Surgical Resection: Mandibulotomy (visor flap + paramedian mandibular swing) approach for posterior oral cavity and oropharynx; lateral pharyngotomy and suprahyoid pharyngotomy for selected hypopharyngeal lesions; total laryngectomy (TL) with tracheoesophageal puncture (TEP) voice prosthesis for T3–T4 glottic/supraglottic cancers failing larynx preservation or as salvage post-CRT. Partial laryngeal procedures (supraglottic laryngectomy, vertical partial laryngectomy) are organ-preserving options for carefully selected early-to-intermediate laryngeal cancers.
• Neck Dissection: Selective neck dissection (SND) — removing at-risk nodal levels (I–III for oral cavity; II–IV for larynx/hypopharynx) — is standard for elective or therapeutic cervical nodal management. Modified radical neck dissection (MRND — preserving sternocleidomastoid, internal jugular vein, and/or accessory nerve) and radical neck dissection (RND) are reserved for extensive nodal disease.
• Microvascular Free-Flap Reconstruction: Following ablative surgery, functional and aesthetic reconstruction uses microsurgically anastomosed free tissue transfers. The fibular osteocutaneous free flap is the gold standard for mandibular reconstruction, restoring jaw continuity and enabling dental implant rehabilitation. The radial forearm fasciocutaneous free flap (RFFF) is preferred for tongue, floor-of-mouth, and pharyngeal defects due to its pliability and thin skin paddle. The anterolateral thigh (ALT) free flap is used for large composite pharyngeal and neck defects. Success rates of free-flap reconstruction exceed 95% at high-volume centers.
• Thyroid and Parathyroid Surgery: Total thyroidectomy (with or without central and lateral neck dissection) for differentiated and medullary thyroid cancer; hemithyroidectomy with intraoperative frozen section for diagnostic purposes. Intraoperative neuromonitoring (IONM) of the recurrent laryngeal nerve (RLN) is standard practice. Robotic thyroidectomy via transaxillary or retroauricular (facelift) approach offers scar-free access.

Radiation THERAPY:

• Intensity-Modulated Radiation Therapy (IMRT): The current standard for all head and neck sites. IMRT delivers sculpted dose distributions conforming to complex three-dimensional tumor volumes while sparing critical structures — parotid glands (reducing xerostomia), spinal cord, brainstem, mandible (reducing osteoradionecrosis risk), optic apparatus, and cochlea. Delivered in 6–7 weeks (30–35 fractions) using simultaneous integrated boost (SIB) or sequential boost technique. Dose: 66–70 Gy to gross disease; 54–60 Gy to elective nodal volumes.
• Volumetric Modulated Arc Therapy (VMAT): An advanced IMRT delivery technique using rotating gantry arcs, reducing treatment time per fraction to 2–5 minutes while maintaining or improving dosimetric quality.
• Proton Beam Therapy (PBT): Available at select Indian and UAE centers, PBT exploits the Bragg peak — depositing maximum dose at a defined depth with near-zero exit dose — offering superior sparing of brainstem, spinal cord, and parotid glands. Particularly advantageous for nasopharyngeal carcinoma, skull base tumors, pediatric head and neck malignancies, and re-irradiation scenarios.
• Stereotactic Body Radiation Therapy (SBRT): High-dose, hypofractionated radiation (5 fractions over 1–2 weeks) for oligometastatic head and neck disease, reirradiation of small recurrent tumors, or as a boost to primary IMRT.

PHASE 1 — PRE-TREATMENT EVALUATION (Days 1–14 before treatment start):

• Day 1–3: Remote consultation with GAF Healthcare's head and neck oncology specialist. Upload all prior imaging, biopsy reports, and histopathology. MDT review initiated.
• Day 4–7: Arrival in India or UAE. Comprehensive in-person evaluation: repeat or supplementary imaging (MRI primary site, PET-CT if not recent <6 weeks), panendoscopy under GA for direct tumor assessment and mapping biopsies if needed.
• Day 8–10: Multidisciplinary tumor board presentation and consensus treatment plan. Simultaneous: dental clearance and extractions if required pre-radiation; baseline audiogram; nutritional assessment and PEG/NGT planning; speech-language pathology baseline swallowing assessment; anesthesiology pre-operative clearance.
• Day 11–14: Radiation planning CT simulation with thermoplastic immobilization mask fabrication; radiation target volume delineation (GTV, CTV, PTV) and IMRT/VMAT/proton plan optimization; dosimetric review and physics QA.

PHASE 2A — SURGICAL TREATMENT (for resectable disease; approximately Days 14–35):